ity is associated with an inhibition of COX metabolization of The nicotine-derived 4-(methylnitrosamino)-1-(3-pyridyl)-arachidonic acid (AA) to prostaglandin E 2 (PGE 2 ) (7). We 1-butanone (NNK), present in tobacco smoke, is most recently demonstrated that these drugs inhibit NNK-induced likely involved in lung carcinogenesis in smokers. We PGE 2 synthesis in tumor-bearing mice (4). COX-1 and -2 are demonstrated previously that non-steroidal anti-inflamencoded by separate genes (8). COX-1 expression appears to matory drugs (NSAIDs) inhibit NNK-induced lung tumobe tissue-and cell-specific although almost nothing is known rigenesis, although the mechanism(s) is unknown. The about its mechanism of regulation. On the other hand, COXpresent study demonstrates that, in U937 human macro-2 is not expressed constitutively in the majority of the cell phages, cyclooxygenase (COX)-1 and -2 are involved in the types, but can be induced through multiple signaling pathways bioactivation of NNK to electrophilic mutagenic inter-(8). More importantly, the expression of COX-2 is significantly mediates. We observed that acetylsalicylic acid and NShigher in human lung adenocarcinomas than in normal tissue 398 decrease COX-dependent NNK activation in U937 (9). The mechanism(s) of inhibition of lung tumorigenesis by cells by 66 and 37%, respectively. NSAIDs also decrease NSAIDs remains unknown, and the relationship between NNK prostaglandin E 2 (PGE 2 ) synthesis, which is induced in a metabolism and COX expression has not been established. dose-dependent manner, reaching a 7-fold increase, in NNK bioactivation leads to the production of reactive NNK-treated human U937 cells. We observed that NNK oxygen species (ROS) (10). ROS are known to activate the induces COX-1 expression and activates the nuclear factornuclear factor-κB (NF-κB), which acts as a positive regulatory κB (NF-κB), in U937 cells. N-acetyl-L-cysteine and pyrrolidelement of COX-2 expression (11,12). We hypothesize that inedithiocarbamate, two inhibitors of reactive oxygen cancer prevention by NSAIDs would involve an inhibition of species (ROS), inhibit NNK-induced PGE 2 synthesis by 41 NF-κB regulating COX expression, resulting in a reduction of and 44%, respectively. These data suggest that ROS, NNK bioactivation. Here, we establish the relationship between generated during pulmonary metabolism of NNK could NNK metabolism and COX expression in U937 human macroact as signal transduction messengers and activate NF-κB, phages. which will subsequently induce COX-1 activity and increase PGE 2 synthesis. These results reveal a novel aspect of Materials and methods tobacco carcinogenesis, and give us insight into the mechanisms of chemoprevention by NSAIDs. Accordingly, inhibiCell line tion of NF-κB activation, leading to the inhibition of COX,
Introduction
into adherent macrophages (14) . Adherent cells were incubated in fresh complete RPMI 1640 medium in the absence of PMA for 6 h. Viability was
The nicotine-derived N-nitrosamine, 4-(methylnitrosamino)-1-Ͼ95% as determined by trypan-blue dye exclusion.
(3-pyridyl)-1-butanone (NNK), present in tobacco smoke, is NNK metabolism likely to be an important factor in the etiology of lung cancer Differentiated cells (1ϫ10 6 ) were stimulated with LPS (100 ng; Sigma-(1). P450 monooxygenases activate NNK in human lungs (2) . Pharmaceutical, Raritan, NJ) ( Table I ). The drugs were initially dissolved in a solution of ethanol:medium, to reach final concentrations of 1.0 mM (SKF NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NSAIDs, non-steroidal anti-inflammatory drugs; PG, prostaglandin; PMA, phorbol 12-myristate 525A) or 50 µM (all other drugs). Supernatants were collected after a 48 h incubation period. A preliminary study showed that NNK metabolism was 13-acetate; ROS, reactive oxygen species. (Table I ). This expression of metabolite (Cayman Chemical) as described previously (20) . formation accounted for loss of radioactivity in the cell pellet and during NNK analysis (recovery was between 40 and 60%).
Results

Assay of AA metabolism
Differentiated cells (1ϫ10 6 ) were resuspended in 1 ml of medium with 3 µCi
In this study, we document the interaction between NNK determined by bicinchoninic acid) were applied on a 10% SDS-PAGE minigel 0.154 pmol/million cells/h) and N-oxidation (11.3%; 0.047 (18) . After transfer to a polyvinylidene difluoride membrane and overnight pmol/million cells/h) metabolites than non-stimulated cells (P blocking with 5% dried milk in TBS, the membrane was incubated for 2 h with human COX-1 or -2 monoclonal antibodies (1:1000) (Cayman Chemicals) Ͻ 0.05) (no. 2). To determine the relative importance of P450 or with human IκB-α monoclonal antibody (1:2000) (Santa Cruz Biotechnomonooxygenases contribution in human macrophages, we logy Inc., Santa Cruz, CA), washed and then incubated for 1 h with the selected SKF-525A, a specific inhibitor of P450 monooxygensecond peroxidase-conjugated antibody (1:5000). The immune complex was ases (21). At 1.0 mM, we expected a complete inhibition of gesting that COX-2 bioactivates NNK (no. 5) (22) . ASA, a COX-1 and -2 inhibitor, was even more potent than NS-398, leading us to conclude that COX-1 would also metabolize Induction of COX-1 expression by NNK NNK. The inhibition by A-79175, a specific 5-lipoxygenase inhibitor, demonstrates the involvement of a 5-lipoxygenaseThe increase in AA metabolism following NNK exposure suggests that COX-1 and/or COX-2 protein were induced. dependent activation of NNK (no. 9) (23). Tepoxalin, a dual COX-lipoxygenases inhibitor (24, 25) was the most effective COX-1 protein was detected in PMA-differentiated U937 cells (Figure 3a) . Surprisingly, immunoblot analysis revealed that of the drugs tested, reducing NNK bioactivation by 55%, thus confirming our conclusion above (no. 10). In order to determine NNK increased the amount of COX-1 in a dose-dependent manner. This increase was already observed after 6 h, but was whether NF-κB regulates COX expression in U937, we used CAPE or capsaicin, two inhibitors of NF-κB activation (26, 27) , higher after an 18 h incubation with NNK. As expected, LPS did not induce COX-1 protein level. Furthermore, we observed, which decreased NNK activation to the same extend as COX inhibitors (Table I, nos 7 and 8) . Furthermore, we demonstrated by northern blotting, that COX-1 mRNA was elevated in 1 mM NNK-treated U937 after 18 h. Results of densitometry, by western blotting that CAPE and capsaicin inhibited COX-2 expression in LPS-stimulated cells (Figure 1) . expressed in arbitrary units as the ratio of COX-1 mRNA on 18S rRNA, were 6.2 Ϯ 0.6 (n ϭ 2) for untreated cells and NNK-induced metabolization of exogenous AA in U937 8.2 Ϯ 0.8 (n ϭ 2) for NNK-treated cells (P Ͻ 0.05, Student's The extent of exogenous [ 3 H]AA metabolism, reflected by the t-test) (Figure 4 ). level of all five major and stable eicosanoids: 6Keto-PGF 1α , Mechanism(s) of COX-1 induction by NNK TXB 2 , PGF 2α , PGE 2 and PGD 2 , was increased by NNK treatment. LPS (100 ng, 6 h), used as positive control, doubled
To elucidate the mechanism(s) of induction of COX-1 by NNK, we measured the level of the major AA metabolite, eicosanoid synthesis from [ 3 H]AA (data not shown). As shown in Figure 2 , eicosanoid synthesis was statistically higher in PGE 2 , secreted by U937 cells. We observed a dose-dependent induction of PGE 2 synthesis by NNK (r 2 ϭ 0.99) (Figure 5a ). NNK (250 and 500 µM)-treated cells. Used as control, for COX-2 induction, LPS (100 ng, 6 h) increased PGE 2 synthesis 7-fold (data not shown). Another nitrosamine requiring bioactivation, NDMA, increased PGE 2 synthesis. In contrast, NNKOAc and NDMAOAc, which produce selectively alkylating intermediates, did not induce PGE 2 synthesis (Figure 5a (500 µM) in the culture medium and PGE 2 released was measured after an
Absence of COX-2 induction by NNK
18 h incubation period. Data are expressed as the percentage increase from unstimulated cells and are the means of two determinations. SE Ͻ 10%.
As expected, COX-2 protein was not observed in unstimulated cells (Figure 1 ). The addition of 1 mM NNK did not induce COX-2 expression during a 2-18 h exposition period ( Figure  (Figure 3c ). We concluded that NNK activates NF-κB in human macrophages. 3b). In contrast to NNK, a 4 h LPS treatment had no effect on the level of COX-1 but induced COX-2. This suggests differences in the mechanisms of COX induction by LPS and Discussion NNK. To confirm the absence of COX-2 induction, we added NNK is a pro-carcinogen which is enzymatically activated NS-398 to NNK treated cells and measured the level of PGE 2 .
into highly potent inducers of lung carcinogenesis (3). Average As expected, this specific COX-2 inhibitor did not inhibit intake of NNK in smokers is 28 nmol per day or 410 µmol NNK-induced PGE 2 synthesis (Figure 5b) , whereas ASA, an in 40 years (30) . In this study, high concentrations of NNK inhibitor of both COX-1 and -2, decreased PGE 2 level.
had to be used to measure the effects of this carcinogen in Inhibition of IκB-α by NNK human cells. Even if high doses of NNK were required, low concentrations of reactive metabolite intermediates were To support the hypothesis suggesting the involvement of NF-κB activation in NNK-induced COX expression, we measured produced. Furthermore, cells were exposed to NNK for only 18 h, whereas smokers are exposed to this carcinogen for the level of IκB-α. In resting cells, NF-κB is non-covalently associated with cytoplasmic inhibitory proteins such as IκB-years. Here, we observed that NNK is bioactivated by COX-1 and -2 in human U937 macrophages, in addition to P450 α (reviewed in refs 28,29) . Activation of NF-κB induces a cascade of events leading to the phosphorylation of IκB-α monooxygenases and lipoxygenases. This is the first observation of a cyclooxygenase-dependent pathway of NNK bioactivand its subsequent proteolytic degradation (28, 29) . IκB-α degradation, visualized by western blotting, correlates with ation in human cells. We also observed that NNK induces prostaglandin synthesis in U937 human macrophages. Quite NF-κB translocation to the nucleus, as measured by nuclear shift assay (28, 29) . In this study, a basal level of IκB-α was unexpectedly, NNK induces COX-1 expression but has no effect on COX-2 protein level. We also demonstrate, for the detected in the cytosolic fraction of unstimulated cells, whereas after NNK challenge, IκB-α was almost completely degraded first time, that NNK activates NF-κB in macrophages and we bioactivated by human lung cells, either as freshly unseparated cell digest, alveolar type II cells or alveolar macrophages (35) . We observed similar inhibition of NNK metabolism by blocking either COX activity or NF-κB activation. Interestingly, NF-κB is a positive regulatory element of the COX-2 response (11,12). Taken together, these data suggest a COX-dependent pathway of NNK metabolism in human lung which correlates with NF-κB activation. COX inhibitors, such as NSAIDs, prevent lung tumorigenesis by a still unknown mechanism of action (4,6). Our data suggest that NSAIDs, which prevent the activation of NNK to mutagenic electrophilic intermediates, act as anti-initiating agents in lung carcinogenesis. We observed previously that NNK treatment increases plasma PGE 2 levels in A/J mice (4). This observation led to the hypothesis that NNK could induce AA metabolism. Both was quite unexpected (8). Although not common, COX-1 induction has previously been observed in human breast Previous human bioactivation studies of NNK have been restricted to whole lung tissues or microsomal preparations, tumors, in gastric mucosa from Helicobacter pylori-infected patients and in monocytoid cells treated with phorbol ester rather than involving specific cell populations. These approaches cannot provide characteristics of specific pulmon-(37-39). The COX-1 gene is generally considered to be a noninducible housekeeping gene, but details on the regulation of ary cell populations. In these systems, P450 monooxygenases and lipoxygenases have been shown to metabolize NNK (2, 31) .
COX-1 expression are unknown. Nevertheless, Jims et al. (40) demonstrated that transcriptional activity of the COX-1 gene We demonstrated previously that purified ovine COX-1 and -2 activate NNK (4). Because they represent a specific human is significantly increased by interleukin-1β and tumor growth factor-β in prostate cancer cells. Furthermore, Wölfe et al. lung cell population and express COX isoenzymes, U937 macrophages were selected for this study (15). Furthermore, (41) recently observed that a 7 week treatment with the tumor promoter 2,3,7,8-tetrachlorodibenzo-p-dioxin induced the macrophages are indirectly implicated in carcinogenesis; they can serve as both positive and negative mediators of the expression of COX-1 in mouse fibroblasts, up to 2-fold. Our observations further suggest that the mechanism of COX immune system, and may contribute up to half of a lung tumor's mass (reviewed in ref. 32 ). Here, we show for the induction by NNK and LPS are different. LPS, a well known COX-2 inducer, does not affect COX-1 expression in U937 first time that human U937 macrophages metabolize NNK. This suggests that alkylating intermediates produced during cells (Figure 3a) (15). Our data confirm that prevention of NNK-induced carcinogenesis by NSAIDs involves the NNK activation by macrophages followed by migration to target pulmonary cells could generate migrations in these cells inhibition of COX-1 and/or -2. PGs, such as PGE 2 , have multifunctional roles in controlling growth, metastasis and the and initiate lung tumor development. In U937 cells, NNK bioactivation involves more than the P450 monooxygenases.
host immune function (42) . COX-2 is not constitutively expressed in U937 cells, and Smith et al. (2) concluded that P450 monooxygenases mediate Ͻ50% of the total NNK metabolism in human lungs. PMAthe expression of this enzyme by NNK was not observed under our experimental conditions. The absence of induction differentiated U937 cells express COX-1 and -2 mRNA and corresponding proteins (33) . Indeed, a significant finding of by NNK in U937 human macrophages does not diminish the importance of COX-2 in carcinogenesis. El-Bayoumy et al. our study was that COX-1 and -2 metabolize NNK (Table I) . We observed that 14.9% of the total amount of NNK was (43) demonstrated that NNK increasingly induces levels of COX-2 expression with progressive stages of lung tumorigenactivated by α-carbon hydroxylation, a level higher than reported previously in other human systems, such as lung esis in rats. This suggests that COX-2 could be expressed at a later stage of carcinogenesis. In fact, Olivo et al. (44) microsomes or explants. However, experimental conditions were not comparable (2, 34) . We demonstrated previously that reported that COX-2 expression is a further event to aberrant crypt foci formation, which are preneoplastic lesions in colon NNK was metabolized by purified ovine COX-1 and -2, and that anti-COX inhibited NNK activation in mouse lung (4) .
cancer. Furthermore, COX-2 was shown to be the constitutively expressed isoform in cultured human lung epithelial cells, and Our results are in line with a study showing that NNK is was induced in human lung adenocarcinomas, which are
